Drug intelligence / Profile preview

PF-07872445

Development stage: Unknown
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PF-07872445 is an investigational component of an expanded multivalent pneumococcal conjugate vaccine (PCV) developed by Pfizer. It consists of a specific *Streptococcus pneumoniae* capsular polysaccharide conjugated to a carrier protein, designed to elicit a T-cell dependent immune response. This component is being evaluated in combination with other conjugates (including those in Prevenar 20) to extend serotype coverage for the prevention of pneumococcal diseases such as pneumonia, meningitis, and bacteremia in infants. It is currently in Phase 3 development as part of a next-generation PCV regimen.

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on PF-07872445.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07872445.

Explore the full profile